Remedies Centred Around Diagnostics and Metabolic Solutions
Your One-Stop-Shop for Healthier Living and Disease Prevention
Dynamic Diagnostic And Nutraceutical Innovation

Diagnostics
The world’s first blood test for the early detection of all cancers.

Sugars
Natural sugars that improve everyday well-being.

Pharma
Research and development of a prodrug to improve cancer treatment success rates.
Dynamic Diagnostic And Nutraceutical Innovation
With its translational approach and TKTL1 focus, RMDM is driving targeted medical solutions while creating a biological model for health- bridging molecular research with real-world clinical strategies.
Diagnostics
The world’s first blood test for the early detection of all cancers.
Sugars
Natural sugars that improve everyday well-being.
Pharma
Research and development of a prodrug to improve cancer treatment success rates.
New Release: 2024 Edition of PanTum Detect Whitepaper
This 2024 edition highlights groundbreaking findings in liquid biopsy and multi-cancer detection, demonstrating the immense potential of the PanTum Detect test to transform early cancer screening programs.
Dive into the comprehensive analysis and see how PanTum Detect can provide a first point of information that will help save more lives and meet cancer targets in the UK and worldwide.

Latest News
Changing Preventative Care in the Middle East
Preventative healthcare in the Middle East is undergoing a significant transformation. With chronic diseases on the rise and late-stage diagnoses still far too common, the introduction of innovative diagnostics, such as the PanTum Detect blood test, could signal a major…
PanTum Detect® Now Available at the Doctors Centre Polyclinic in Dubai
We’re excited to announce that RMDM Group’s PanTum Detect® blood test is officially live at the Doctors Centre Polyclinic in Dubai.
Welcoming Dr Joachim Stein to RMDM
A highly respected figure in the field of gynaecology and obstetrics, Dr Stein brings with him more than two decades of clinical excellence, scientific contribution, and a visionary approach to women’s health and preventive medicine.
Reducing Late-Stage Diagnoses: How PanTum Detect Fits into Emerging MCED Strategies
New modelling shows annual multi-cancer early detection (MCED) tests could cut late-stage diagnoses by 49%. RMDM Group’s PanTum Detect goes further—identifying both early-stage cancers and precancerous changes with high accuracy. With a positive predictive value of 66.47%, it offers a…
Harnessing Sugar’s Dual Role in Cancer: From Fuel to Therapeutic Target
While sugar is often seen as a cancer culprit, new research shows it can also be a powerful tool in diagnosis, treatment, and prevention. From the tumour-fuelling role of glucose to the therapeutic potential of functional sugars like mannose, this…
New Research Links Sugar-Sweetened Beverages to Oral Cavity Cancer Risk in Women
A recent study published in JAMA Otolaryngology has uncovered a concerning link between the consumption of sugar-sweetened beverages (SSBs) and an increased risk of oral cavity cancer in women, including both smokers and non-smokers. The findings show that women who…
Advancing Prostate Cancer Detection: The Role of AI and Blood-Based Screening
The AI-powered prostate cancer test developed by EDX Medical Group represents a major advancement in early detection. By analysing over 100 biological markers in blood and urine samples, it offers a more accurate assessment of prostate cancer risk than traditional…
NHS Backlogs, Less Rhetoric and More Solutions by Dr. Letizia Gulino, Head of Science and Technology RMDM
We are witnessing a crucial moment for the NHS as it promises to reduce waiting lists and deliver timely care. This commitment resonates with patients and healthcare professionals. However, while the intentions behind these proposals are laudable, critical questions remain…
Reforming Prostate Cancer Testing: Chris Hoy’s Urgent Appeal for Change
Olympic cyclist Sir Chris Hoy is advocating for improved prostate cancer tests for younger men following his terminal diagnosis in September 2023. His recent interview with the BBC reveals the limitations of the NHS’s current protocol for prostate cancer testing.
Government and Tech Innovators Unite to Advance Cancer Detection: The Potential of Pantum Detect
In a recent press release, the UK government outlined an initiative to boost tech deals aimed at further innovating cancer diagnosis in the country. This plan follows the Darzi review, which highlighted the critical state of the NHS, particularly the…